Sylvia Hsu

Prof. Dr. Sylvia Hsu

Department of Dermatology, Temple University Lewis Katz School of Medicine, Philadelphia, PA 19140, USA

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 October 2021 in Medicina
Verified
Journal Article
Open access
PDF file
AMAli M. Malik
Ali M. Malik
STSarah Anne Tupchong
Sarah Anne Tupchong
SHSimo Huang
Simo Huang
AAAbhirup Are
Abhirup Are
SHSylvia Hsu
Sylvia Hsu
KMKiran Motaparthi
Kiran Motaparthi
Clinicians may encounter a variety of skin conditions that present with vesiculobullous lesions in their everyday practice. Pemphigus vulgaris, pemphigus foliaceus, IgA pemphigus, and paraneoplastic pemphigus represent the spectrum of autoimmune bullous dermatoses of the pemphigus family. The pemphigus family of diseases is characterized by significant morbidity and mortality. Considering the risks associated with a delayed diagnosis or misdiagnosis and the potential for overlap in clinical features and treatment, evaluation for suspected pemphigus disease often requires thorough clinical assessment and laboratory testing. Diagnosis is focused on individual biopsies for histopathology and direct immunofluorescence. Additional laboratory methods used for diagnosis include indirect immunofluorescence and enzyme-linked immunosorbent assay. Recent advancements, including anti-CD20 therapy, have improved the efficacy and reduced the morbidity of pemphigus treatment. This contribution presents updates on the pathophysiology, clinical features, diagnostic work-up, and medical management of pemphigus. Improved strategies for diagnosis and clinical assessment are reviewed, and newer treatment options are discussed.

9 October 2021 in Dermatology and Therapy
Verified
Journal Article
Open access
PDF file
AMAlan Menter
Alan Menter
AVAbby S. Van Voorhees
Abby S. Van Voorhees
SHSylvia Hsu
Sylvia Hsu
Pustular psoriasis is an unusual form of psoriasis that frequently presents clinical challenges for dermatologists. The condition presents with pustules on an erythematous background and has two distinct subtypes: localized disease on the palms and soles, called palmoplantar pustulosis (PPP), and generalized pustular psoriasis (GPP). The involvement of the fingers, toes, and nails is defined as a separate localized variant, acrodermatitis continua of Hallopeau, and is now thought to be a subset of PPP. The rarity of pustular psoriasis frequently makes the correct diagnosis problematic. In addition, treatment is limited by a relative lack of evidence-based therapeutic options. Current management is often based on existing therapies for standard plaque psoriasis. However, there remains a need for treatments with high, sustained efficacy and a rapid onset of action in pustular psoriasis. Recent advances in understanding of the pathogenesis of pustular psoriasis have provided insights into potential therapies. Treatment of pustular psoriasis is generally determined by the extent and severity of disease, and recent years have seen an increasing use of newer agents, including biologic therapies. Current classes of biologic therapies with US Food and Drug Administration and European Medicines Agency approval for treatment of moderate-to-severe plaque psoriasis in the USA (and elsewhere) include tumor necrosis factor alpha inhibitors (adalimumab, certolizumab pegol, etanercept, infliximab), interleukin (IL)-17 inhibitors (brodalumab, ixekizumab, secukinumab), an IL-12/23 inhibitor (ustekinumab), and IL-23 inhibitors (guselkumab, risankizumab, tildrakizumab). Recently, specific inhibitors of the IL-36 pathway have been evaluated in GPP and PPP, including spesolimab, an IL-36 receptor inhibitor which has shown promising results in GPP. The emerging drugs for pustular psoriasis offer the possibility of rapid and effective treatment with lower toxicities than existing therapies. Further research into agents acting on the IL-36 pathway and other targeted therapies has the potential to transform the future treatment of patients with pustular psoriasis. This article reviews the clinical features of PPP and GPP, and current understanding of the genetics and immunopathology of these conditions; it also provides an update on emerging treatments.

4 October 2021 in Medicina
Verified
Journal Article
Open access
PDF file
Valeryia PratasavaValeryia Pratasava
Valeryia Pratasava
VSVikram N. Sahni
Vikram N. Sahni
ASAishwarya Suresh
Aishwarya Suresh
SHSimo Huang
Simo Huang
AAAbhirup Are
Abhirup Are
KMKiran Motaparthi
Kiran Motaparthi
The pemphigoid family of dermatoses is characterized by autoimmune subepidermal blistering. The classic paradigm for pemphigoid, and the most common member, is bullous pemphigoid. Its variable clinical presentation, with or without frank bullae, is linked by significant pruritus afflicting the elderly. Mucous membrane pemphigoid is an umbrella term for a group of subepidermal blistering dermatoses that favor the mucosal membranes and can scar. Epidermolysis bullosa acquisita is a chronic blistering disorder characterized by skin fragility, sensitivity to trauma, and its treatment-refractory nature. Clinicians that encounter these pemphigoid disorders may benefit from an overview of their clinical presentation, diagnostic work-up, and therapeutic management, with an emphasis on the most frequently encountered pemphigoid disease, bullous pemphigoid.

23 September 2021 in Medicina
Verified
Journal Article
Open access
PDF file
MSMorgan Sussman
Morgan Sussman
ANAnthony Napodano
Anthony Napodano
SHSimo Huang
Simo Huang
AAAbhirup Are
Abhirup Are
SHSylvia Hsu
Sylvia Hsu
KMKiran Motaparthi
Kiran Motaparthi
The similarity between pustular psoriasis (PP) and acute generalized exanthematous pustulosis (AGEP) poses problems in the diagnosis and treatment of these two conditions. Significant clinical and histopathologic overlap exists between PP and AGEP. PP is an inflammatory disorder that has numerous clinical subtypes, but all with sterile pustules composed of neutrophils. AGEP is a severe cutaneous adverse reaction that is also characterized by non-follicular sterile pustules. Clinical features that suggest a diagnosis of PP over AGEP include a history of psoriasis and the presence of scaling plaques. Histologically, eosinophilic spongiosis, vacuolar interface dermatitis, and dermal eosinophilia favor a diagnosis of AGEP over PP. Importantly, PP and AGEP vary in clinical course and treatment. PP treatment involves topical steroids, oral retinoids, and systemic immunosuppressants. Newer therapies targeting IL-36, IL-23, IL-1, and PDE-4 have been investigated. The removal of the offending agent is a crucial part of the treatment of AGEP.

15 February 2020 in Journal of Cosmetic Dermatology
Verified
Journal Article
Closed access
PDF file
TLTyler Long
Tyler Long
AGAkhil Gupta
Akhil Gupta
SMSteven Ma
Steven Ma
SHSylvia Hsu
Sylvia Hsu

5 July 2019 in British Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
SHSylvia Hsu
Sylvia Hsu
LGL.J. Green
L.J. Green
MLM.G. Lebwohl
M.G. Lebwohl
JWJ.J. Wu
J.J. Wu
ABAndrew Blauvelt
Andrew Blauvelt
AJA.A. Jacobson
A.A. Jacobson